Latest market price
11.37
-0.53-4.45%
OverviewShort InterestFilings
FDMTQT574D Molecular Therapeutics, Inc.·NASDAQ
11.37-4.45%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-2.72Insider Own33.98%Shs Outstand55.24MPerf Week3.08%
Market Cap628.13MForward P/E—EPS next Y-4.09Insider Trans-2.26%Shs Float42.55MPerf Month-16.83%
Enterprise Value301.13MPEG—EPS next Q-1.04Short Float27.10%Perf Quarter10.82%
Income-180.00MP/S6.83EPS this Y—Short Ratio12.20Perf Half Y20.44%
Sales92.00MP/B1.54EPS next Y—ROA-36.37%Short Interest11.53MPerf YTD51.60%
Book/sh7.39P/C1.74EPS next 5Y—ROE-41.33%52W High16.93 -32.84%Perf Year0.44%
Cash/sh6.53P/FCF—EPS past 3/5Y—ROIC-43.77%52W Low6.96 63.36%Perf 3Y7.26%
Dividend Est.—EV/EBITDA—Sales past 3/5Y204.86% 43.44%Gross Margin42.00%Volatility8.98% 7.40%Perf 5Y-65.48%
Dividend TTM—EV/Sales3.27EPS Y/Y TTM—Oper. Margin-214.24%ATR (14)0.96Perf 10Y—
Dividend Ex-Date—Quick Ratio8.03Sales Y/Y TTM—Profit Margin-194.74%RSI (14)41.05Recom2.29
Dividend Gr. 3/5Y—Current Ratio8.03EPS Q/Q-6.12%SMA20-7.70%Beta2.88Target Price29.67
Payout0.00%Debt/Eq0.08Sales Q/Q—SMA50-16.56%Rel Volume0.72Prev Close11.90
Employees196LT Debt/Eq0.08EarningsNov 10SMA2004.39%Avg Volume1.02MPrice11.37
IPO DateDec 11, 2020Option/ShortYes / YesEPS/Sales Surpr.-2.29% 4.45%Net Debt/EBITDA—Volume734,781Change-4.45%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-01-26ReiteratedB.Riley Financial$37
Sep-14-26UpgradeCantor FitzgeraldNeutral → Overweight$20
Aug-13-26ReiteratedGoldman SachsBuy$33 → $32
May-08-26ReiteratedGoldman SachsBuy$38 → $33
Nov-11-25ReiteratedBarclaysOverweight$45 → $33
Oct-31-25ReiteratedLeerink PartnersOutperform$17
Oct-21-25ReiteratedRBC CapitalOutperform$40 → $26
Sep-23-24DowngradeCantor FitzgeraldOverweight → Neutral
Sep-19-24ReiteratedBMO CapitalOutperform$40
Sep-19-24ReiteratedLoop Capital Markets$39
Latest News· Times ET
Nov-02-26
Nov-02-2611:01AM
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?zacks.com
Oct-22-26
Oct-22-2607:02AM
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapymarketbeat.com
02:27AM
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price TargetBenzinga
Oct-21-26
Oct-21-2606:24PM
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcriptseekingalpha.com
04:15AM
Reviewing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT)defenseworld.net
Oct-16-26
Oct-16-2604:05PM
4DMT Announces New Employment Inducement GrantsYahoo
Oct-13-26
Oct-13-2604:29AM
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90defenseworld.net
Oct-06-26
Oct-06-2604:26AM
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25Benzinga
Oct-05-26
Oct-05-2608:00AM
4DMT to Host Investor Day on October 21, 2026globenewswire.com
Sep-29-26
Sep-29-2605:27PM
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underwayseekingalpha.com
05:24PM
This is the top biotech stock pick from B Riley SecuritiesYahoo
Sep-28-26
Sep-28-2608:00AM
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DMEglobenewswire.com
Sep-25-26
Sep-25-2604:03AM
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga
Sep-24-26
Sep-24-2605:09AM
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stockdefenseworld.net
Sep-21-26
Sep-21-2603:59AM
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokeragesdefenseworld.net
Company

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue9285021—————
Cost of Goods Sold Incl. D&A53814197—————
Gross Profit3978-141-76—————
Selling, General and Administrative Excl. Other50494736—————
Research and Development24019614197—————
Other Operating Expense-54-8-141-97—————
Operating Income-197-160-188-113—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)18192712—————
Net Income Before Taxes-180-140-161-101—————
Income Taxes
0000—————
Consolidated Net Income-180-140-161-101—————
Net Income From Continuing Operations-180-140-161-101—————
Net Income-180-140-161-101—————
EPS (Recurring)-2.72-2.42-2.98-2.58—————
EPS (Basic, Before Extraordinaries)-2.72-2.42-2.98-2.58—————
EPS (Diluted)-2.72-2.42-2.98-2.58—————
EBITDA-185-132-154-95—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio8.655.12—37.63—————
Gross Margin42.3991.76—-361.90—————
Operating Margin-214.13-188.24—-538.10—————
Net Margin-195.65-164.71—-480.95—————
Shares Outstanding70585439—————
Market Capitalization796435301790—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$18.35$14.90$11.45$8.00$4.55● Close Price0.00M0.38M0.76M1.15M1.53MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bizily ScottChief Legal OfficerOct 16 '26Option Exercise4.141,6356,76910,252Oct 20
Bizily ScottChief Legal OfficerOct 16 '26Sale12.841,63520,9938,617Oct 20
Kirn DavidDirector, OfficerOct 05 '26Sale12.9258,333753,937709,153Oct 07
Bizily ScottChief Legal OfficerSep 16 '26Option Exercise4.141,6356,76910,252Sep 22
Bizily ScottChief Legal OfficerSep 16 '26Sale13.651,63522,3188,617Sep 22
Kirn DavidDirector, OfficerSep 14 '26Sale13.9058,333811,004767,486Sep 16
Bizily ScottChief Legal OfficerSep 01 '26Option Exercise6.495843,7909,201Sep 03
Bizily ScottChief Legal OfficerSep 01 '26Sale14.005848,1768,617Sep 03
Kirn DavidDirector, OfficerAug 19 '26Option Exercise4.1450,000207,000894,895Aug 21
Kirn DavidDirector, OfficerAug 19 '26Sale15.7569,0761,088,273825,819Aug 21
Bizily ScottChief Legal OfficerAug 17 '26Option Exercise4.141,6356,76910,252Aug 17
Bizily ScottChief Legal OfficerAug 17 '26Sale12.201,63519,9478,617Aug 17
Bizily ScottChief Legal OfficerAug 13 '26Sale12.001,63519,6208,617Aug 17
Bizily ScottChief Legal OfficerAug 13 '26Option Exercise4.141,6356,76961,336Aug 17
Kirn DavidDirector, OfficerAug 04 '26Sale10.2326,842274,596844,895Aug 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.